Save time and jump to the most important pieces.
New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, Pa., Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE).
DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the "Offer") by Harmony Biosciences Holdings, Inc. ("Harmony") and its wholly owned subsidiary, Xylophone Acquisition Corp. ("Purchaser"), to purchase all outstanding shares of Zynerba common stock. The Zynerba Board of Directors unanimously recommends that Zynerba stockholders tender their shares pursuant to the Offer. Key Information to Know Tender Deadl
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. ("Harmony"). Fellow Zynerba Pharmaceuticals Stockholders, We urge you to promptly tender your shares in response to the pending tender offer (the "Offer") by Harmony and its wholly owned subsidiary, Xylophone Acquisition Corp. ("Purchaser"). As previously disclosed, the Offer is to purchase all of the issued and outstanding shares of the co
Roth Capital reiterated coverage of Zynerba Pharmaceuticals with a rating of Buy and set a new price target of $7.25 from $8.00 previously
Canaccord Genuity resumed coverage of Zynerba Pharmaceuticals with a rating of Buy and set a new price target of $18.00
15-12G - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
EFFECT - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
POS AM - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
SC 13G/A - Zynerba Pharmaceuticals, Inc. (0001621443) (Subject)
SC 13G - Zynerba Pharmaceuticals, Inc. (0001621443) (Subject)
SC 13G/A - Zynerba Pharmaceuticals, Inc. (0001621443) (Subject)
DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Legal Officer and Corporate Secretary. He will assume the duties of Suzanne Hanlon who will retire from her position at the end of February 2022. "We are excited to have Al join our senior leadership team. He is an experienced legal and business executive who brings significant strategic and hands-o
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced the recent appointments of Richard Baron to Immunome’s Board of Directors and as Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer and Corporate Secretary. The company also today announced that its President and Chief Executive Officer, Purnanand Sarma, Ph.D. is the recipient of TiE Boston’s 2020 Lifetime Achievement Award. The award recognizes individuals who have made invaluab
4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)
New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, Pa., Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE).
PLYMOUTH MEETING, Pa. and DEVON, Pa., Aug. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE), a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS). Under the terms of the definitive agreement, Harmony
– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments – – Safety data reinforce excellent tolerability profile of Zygel – – Company will focus resources on FXS and 22q development – – Cash runway extended through the end of 2023 / early 2024 – – Zynerba to host conference call and webcast tomorrow, June 22, 2022 at 9:00 a.m. ET – DEVON, Pa., June 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced positive top line results from the explorat
Healthcare company Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) on Wednesday. What Happened Harmony's offer to acquire all outstanding shares of Zynerba for $60 million or $1.1059 per share in cash, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million or approximately $2.5444 in additional cash per share, subject to the achievement of specific clinical, regulatory and sales milestones expired at 5:00 p.m. ET time on Tuesday, October 10, 2023. Following the acceptance of the tendered shares, Harmony
In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), today announced that Xylophone Acquisition Corp., a wholly owned subsidiary of Harmony, has extended the expiration of its tender offer to acquire all of the outstanding shares of common stock of Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE) to 5:00 p.m., New York City time, on Tuesday, October 10, 2023, unless further extended. The tender offer was previously scheduled to expire at 5:00 p.m., New York City time, on Tuesday, September 26, 2023. All other terms and conditions of the tender offer remain unchanged.The depositary for the tender offer has advised
GAINERS: GreenGro Technologies (OTC:GRNH) shares closed up 28.89% at $0.00 Rocky Mountain High (OTC:RMHB) shares closed up 18.75% at $0.01 iAnthus Capital Hldgs (OTC:ITHUF) shares closed up 9.72% at $0.03 Target Group (OTC:CBDY) shares closed up 9.07% at $0.01 Urban-gro (NASDAQ:UGRO) shares closed up 8.46% at $1.41 Trulieve Cannabis (OTC:TCNNF) shares closed up 7.50% at $6.74 Kaya Holdings (OTC:KAYS) shares closed up 6.73% at $0.05 Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 6.11% at $6.43 4Front Ventures (OTC:FFNTF) shares closed up 5.96% at $0.25 Global Hemp Group (OTC:GBHPF) shares closed up 5.56% at $0.00 Cara Therapeutics (NASDAQ:CARA) shares closed up 4.68% at $1.79 RIV Capi